BU BÖLÜM HAKKINDA
Bob Diamond, CEO of Atlas Merchant Capital and former Barclays CEO, joins to assess market conditions, policy risk and where investors should be focusing now. The show also explores growing buzz around a potential SpaceX IPO and what a deal of that size could mean for markets and investor demand. Nike remains under pressure. Williams Trading analyst Sam Poser explains why he is sticking with a Buy rating even after lowering his price target and why the turnaround may take longer than expected. On the 50th anniversary of Apple’s founding, we look at the next stage of the company’s evolution. Sebastien Page, CIO of T. Rowe Price, outlines the broader investment landscape and how portfolios should be positioned. Christopher Verrone of Strategas walks through the technical setup and key levels investors should watch.
Our Angelica Peebles reports on the FDA approval of Eli Lilly’s daily GLP-1 pill and what it could mean for the weight loss drug market and healthcare stocks. The episode closes with a look ahead at the next catalysts for markets.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
